Ashok B Jain

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years
    A Jain
    Departments of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Liver Transpl 7:623-30. 2001
  2. ncbi Hepatitis C virus and renal failure
    A K B Jain
    Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania 15213, USA
    Transplant Proc 35:416-8. 2003
  3. ncbi Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection
    Ashok B Jain
    Transplantation Institute, The Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Liver Transpl 8:1007-13. 2002
  4. ncbi The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients
    Ashok Kumar B Jain
    Department of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Liver Transpl 8:841-5. 2002
  5. ncbi Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report
    Ashok Kumar B Jain
    Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA
    Liver Transpl 8:838-40. 2002
  6. ncbi Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients
    A K B Jain
    Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, 3601 Fifth Avenue, Falk Medical Building 4th Floor, Pittsburgh, PA 15213, USA
    Transplant Proc 34:1540-1. 2002
  7. ncbi Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis after liver transplantation and long-term survival
    Ashok Jain
    Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Transplant Proc 34:1524-5. 2002
  8. ncbi A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C
    Ashok Jain
    Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Liver Transpl 8:40-6. 2002
  9. ncbi Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report
    Jonathan A Fridell
    Department of Surgery, Indiana University School of Medicine, Indianapolis, USA
    Ther Drug Monit 25:117-9. 2003
  10. ncbi Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantation
    Cataldo Doria
    Department of Surgery, Division of Transplantation, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Exp Clin Transplant 1:48-55. 2003

Detail Information

Publications10

  1. ncbi Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years
    A Jain
    Departments of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Liver Transpl 7:623-30. 2001
    ..05) was the only factor found to be significant between patients who had graft loss versus those who recovered...
  2. ncbi Hepatitis C virus and renal failure
    A K B Jain
    Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania 15213, USA
    Transplant Proc 35:416-8. 2003
  3. ncbi Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection
    Ashok B Jain
    Transplantation Institute, The Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Liver Transpl 8:1007-13. 2002
    ..Further pharmacokinetic studies of ribavirin in LTx patients with varying degrees of renal function may allow the development of an algorithm for the safer use of ribavirin in HCV-positive LTx patients...
  4. ncbi The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients
    Ashok Kumar B Jain
    Department of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Liver Transpl 8:841-5. 2002
    ..Great caution and frequent drug level monitoring are necessary when HAART is introduced or withdrawn in HIV-positive recipients of organ transplants...
  5. ncbi Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report
    Ashok Kumar B Jain
    Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA
    Liver Transpl 8:838-40. 2002
    ..Increase in trough concentration, peak concentration area under the curve concentration, and prolongation of half-life of sirolimus has been shown in a patient who was on a low dose (one fifth the recommended dose) of nelfinavir...
  6. ncbi Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients
    A K B Jain
    Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, 3601 Fifth Avenue, Falk Medical Building 4th Floor, Pittsburgh, PA 15213, USA
    Transplant Proc 34:1540-1. 2002
  7. ncbi Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis after liver transplantation and long-term survival
    Ashok Jain
    Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Transplant Proc 34:1524-5. 2002
  8. ncbi A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C
    Ashok Jain
    Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Liver Transpl 8:40-6. 2002
    ..In addition, there was no difference in HAI or fibrosis score between the two groups. Either MMF has no anti-HCV effect or its immunosuppressive properties overwhelm its antiviral effect in the clinical setting...
  9. ncbi Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report
    Jonathan A Fridell
    Department of Surgery, Indiana University School of Medicine, Indianapolis, USA
    Ther Drug Monit 25:117-9. 2003
    ..It is essential to monitor the blood concentrations of sirolimus and adjust the sirolimus dosage when phenytoin administration begins or ends...
  10. ncbi Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantation
    Cataldo Doria
    Department of Surgery, Division of Transplantation, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Exp Clin Transplant 1:48-55. 2003
    ..Additionally, re-conversion to Tacrolimus for lack of efficacy of Cyclosporine A did not appear to be associated with a recurrence of the condition that caused the initial switch...